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Abstract: Glutathione S-transferase (GST) genes detoxify and metabolize carcinogens, including oxygen free 
radicals which may contribute to salivary gland carcinogenesis. This cancer center-based case-control association 
study included 166 patients with incident salivary gland carcinoma (SGC) and 511 cancer-free controls.  We 
performed multiplex polymerase chain reaction-based polymorphism genotyping assays for GSTM1 and GSTT1 
null genotypes.  Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with multivariable logistic 
regression analyses adjusted for age, sex, ethnicity, tobacco use, family history of cancer, alcohol use and 
radiation exposure. In our results, 27.7% of the SGC cases and 20.6% of the controls were null for the GSTT1 
(P = 0.054), and 53.0% of the SGC cases and 50.9% of the controls were null for the GSTM1 (P = 0.633). The 
results of the adjusted multivariale regression analysis suggested that having GSTT1 null genotype was 
associated with a significantly increased risk for SGC (odds ratio 1.5, 95% confidence interval 1.0-2.3).  
Additionally, 13.9% of the SGC cases but only 8.4% of the controls were null for both genes and the results of the 
adjusted multivariable regression analysis suggested that having both null genotypes was significantly associated 
with an approximately 2-fold increased risk for SGC (odds ratio 1.9, 95% confidence interval 1.0-3.5). The 
presence of GSTT1 null genotype and the simultaneous presence of GSTM1 and GSTT1 null genotypes appear 
associated with significantly increased SGC risk. These findings warrant further study with larger sample sizes. 
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Introduction 
 
Salivary gland carcinoma (SGC) is a rare 
malignancy with an incidence rate of 
approximately 1 per 100,000 population per 
year in the United States [1]. However, the 
incidence of SGC as a proportion of all head 
and neck cancers increased from 6.3% during 
1974 through 1976 to 8.1% during 1998 
through 1999 [1]. SGC may arise in major or 
minor salivary glands and may have a variety 
of histologic and biologic characteristics. The 
parotid gland is the most common anatomic 
site of origin, and mucoepidermoid carcinomas 
and adenoid cystic carcinomas are the most 
frequently occurring histologic types [2,3]. 
Although the etiology of SGC remains unclear, 
prior exposure to radiation has been the most 
clearly identified SGC risk factor [4-6].   This 
type of cancer is special because it is a diverse 
group of neoplasm with differing 
characteristics [7]. 
 
Glutathione S-transferase (GST) genes are 
important in detoxifying and metabolizing 
carcinogens [8].  The GSTs catalyze the 
glutathione conjugation of these toxic and 
mutagenic compounds with electrophilic 
functional groups to prevent adduct formation, 
and thus protect organisms from DNA damage 
or protecting chromosomes from oxidative 
damage [9, 10]. The human cytosolic GST 
system consists of 7 gene classes of 
isoenzymes, designated GST-, GST-μ, GST-, 
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GST-, GST-, GST-, and GST-. Each gene 
class can include several genes [11]. For 
instance, the GST-μ family consists of GST-μ1 
through GST-μ5. The effect of GST 
polymorphisms on genetic susceptibility has 
been investigated for several GST isoenzymes, 
particularly GST-μ1 (GSTM1gene) and GST-1 
(GSTT1gene). Both genes possess null 
genotypes with no enzyme activity. 
Epidemiologic studies have found that 
individuals with homozygous deletions of 
these genes (ie, GSTM1 null or GSTT1 null) 
have an increased risk of cancer at a number 
of different body sites, including the head and 
neck, lungs, breasts, and brain [12-16]. 
 
The frequency of GSTM1 and GSTT1 null 
genotypes may vary in different populations. In 
Caucasian populations, 40%~60% are 
homozygote for the GSTM1 null genotype and 
20%-30% are homozygote for the GSTT1 null 
genotype [17]. In African American 
populations, 30% are homozygote for GSTM1 
null genotype and in the general population, 
15% are missing both GSTM1 and GSTT1 
genes [18, 19]. These polymorphisms may 
result in differences in enzyme activity, which 
may provide a potential mechanism for 
increased susceptibility to cancers including 
SGC in different populations. In addition to 
GSTM1 and GSTT1 null genotypes being less 
efficient at processing carcinogens and radical 
oxygen species, the frequency of p53 somatic 
mutation is greater in patients with the GSTT1 
null genotype compared with patients carrying 
GSTT1 gene [20]. Therefore, understanding 
the variation in individuals in genetic 
susceptibility to SGC caused by these two 
polymorphisms holds great promise for 
primary cancer prevention. Identifying markers 
of SGC risk would greatly enhance cancer 
prevention programs, which is currently 
extremely limited. 
 
In this molecular epidemiologic case-control 
study, we explored the association between 
GSTM1 and GSTT1 null genotypes and the risk 
of SGC, with adjustments for age, sex, 
ethnicity, smoking, drinking, family cancer 
history, and radiation exposure. We 
hypothesized that the lack of GSTM1 and 
GSTT1 isoenzymes puts individuals at risk of 
SGC by limiting their ability to detoxify 
carcinogens resulting from exposures or 
products of oxidative stress. 
 
Materials and methods 
 
Study subjects 
 
This was a tertiary cancer center–based, case-
control study. From April, 1996 to July, 2007, 
patients who presented to the Head and Neck 
Surgery Clinic at The University of Texas M. D. 
Anderson Cancer Center with a diagnosis of 
SGC were recruited into a molecular 
epidemiologic study of nonsquamous cell 
carcinoma of the head and neck before 
undergoing definitive surgical therapy. Final 
histopathologic diagnoses were obtained from 
a review of the medical records. Patients who 
underwent surgical excision or biopsy and 
received a definitive histopathologic diagnosis 
were included in the study. We included 
cancer-free control subjects who had been 
recruited from among spouses and other 
visitors who accompanied patients for a 
molecular epidemiologic study of head and 
neck squamous cell carcinoma from 
November, 1996 to March, 2005. The final 
genotype analysis included 166 SGC cases 
and 511 cancer-free controls. Each study 
subject had completed a self-administered 
questionnaire, providing demographic, 
socioeconomic, risk exposure, and family 
medical history data. A positive family history 
of cancer was defined as reportedly having any 
first-degree relative with a history of cancer 
except for nonmelanoma skin carcinoma. 
Positive radiation exposure was defined as 
whole body or head-and-neck-specific 
radiation exposure. 
 
Smokers were defined as those subjects who 
had smoked more than 100 cigarettes in their 
lifetimes. Subjects who had quit smoking more 
than 1 year before enrollment in the study 
were classified as former smokers, with all 
other smokers considered current smokers. 
Those who had used alcohol at least once a 
week for more than 1 year were defined as 
drinkers; those drinkers who had not drunk 
alcohol for more than 1 year before enrollment 
were defined as former drinkers; and all other 
drinkers were considered current drinkers. 
Ethnicity was categorized by the subject as 
non-Hispanic white or other (Hispanic, African 
American, or Asian). After institutional review 
board–approved informed consent had been 
obtained, each participant had donated 20 mL 
of blood for cell culture and DNA extraction. 
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Genotyping 
 
A leukocyte cell pellet was obtained from the 
buffy coat by centrifugation of 1 mL of whole 
blood. The pellet was used for genomic DNA 
extraction with a DNA blood kit (Qiagen DNA 
Blood Mini Kit; Qiagen, Inc, Valencia, Calif ) 
according to the manufacturer’s instructions. 
We used a multiplex polymerase chain 
reaction (PCR) assay to simultaneously 
determine the presence or absence of the 
GSTM1 and GSTT1 genes and the 
dihydrofolate reductase (DHFR) gene as an 
internal control for amplification failure 
secondary to DNA degradation. The primers 
used for GSTM1 were 5’-GAA CTC CCT GAA 
AAG CTA AAG C-3’ and 5’-GTT GGG CTC AAA 
TAT ACG GTG G-3’, generating a 480–base 
pair (bp) fragment. For GSTT1, the primers 
used were 5’-TTC CTT ACT GGT CCT CAC ATC 
TC-3’ and 5’-TCA CCG GAT CAT GGC CAG CA-3’, 
generating a 215-bp fragment. The primers 
used for DHFR were 5’-CATCGG CAAGAACG 
GGGACCT-3’ and 5’-ACCGAAGCCTCCACCCAGT 
TG-3’, generating a 280-bp fragment. The 
absence of a 480- or a 215-bp band in the 
PCR assay indicated the presence of a GSTM1 
null or a GSTT1 null genotype, respectively. 
When no band was evident at 280 bp, the PCR 
assay was considered unsuccessful, most 
likely owing to degraded DNA because DHFR is 
typically easily amplified. The GSTM1, GSTT1, 
and DHFR genes were coamplified in a 40-μL 
reaction mixture containing 100 ng of genomic 
DNA as the template, 3.5 pmol of each GSTM1 
primer, 2.9 pmol of each GSTT1 primer, 6.2 
pmol of each DHFR primer, 0.1mM 
deoxyribonucleotide triphosphate, 1X PCR 
buffer (50mM potassium chloride, 10mM Tris 
hydrochloride [pH, 9.0 at 25°C], 0.1% Triton X-
100, and 1.5mM magnesium chloride), and 
1.0 U of Taq DNA polymerase (Sigma-Aldrich 
Corp, St Louis, Mo). The PCR profile consisted 
of an initial melting step of 95°C for 5 
minutes; 35 cycles of 95°C for 30 seconds, 
58°C for 35 seconds, and 72°C for 60 
seconds; and a final elongation step of 72°C 
for 10 minutes. The PCR products were 
separated on a 2% agarose gel and 
photographed with a digital imaging system 
(IS-1000; Alpha Innotech Co, San Leandro, 
Calif.). 
 
Statistical analysis 
 
All statistical analyses were two-sided and 
performed with commercially available 
statistical analysis system software (version 
9.1, SAS Institute, Cary, NC). A P value of .05 
was preset as the level of significance. The 
demographic characteristics of the study 
participants were compared using the two-
sided 2 tests to assess differences in age, 
sex, ethnicity, family cancer history, tobacco 
use, alcohol use, and radiation exposure 
frequencies. The GST genotypes were first 
analyzed as a dichotomized variable, with 0 
being the null genotype and 1 being the other 
genotype. Univariate analysis was performed 
to calculate crude odds ratios (ORs) and 95% 
confidence intervals (CIs) for various strata for 
the GSTM1 and GSTT1 genotypes. Adjusted 
ORs were calculated, with adjustment for age, 
sex, ethnicity, tobacco use, alcohol use, family 
cancer history, and radiation exposure, using a 
multivariable logistic regression analysis. For 
the logistic regression analysis, the GST 
genotype was recorded as a dummy variable 
(0.0 for both null, 0.1 for GSTM1 null, and 1.0 
for GSTT1 null). To assess trends, the 
quartered variables were treated as 
continuous variables and fit into the logistic 
regression model.  
 
Results 
 
We included 166 new patients with SGC and 
511 cancer-free controls in this study. The 
demographic characteristics of case subjects 
and controls are shown in Table 1. The cases 
and controls appeared to be adequately 
frequency-matched for sex, ethnicity, family 
cancer history, smoking and drinking status. 
The mean age of the controls was 49.1 ± 11.4 
(median, 48; range, 20-82) years while the 
mean age for the SGC cases was 54.5 ± 14.7 
(median, 54.0; range, 18-90) years. The SGC 
cases were significantly older than the controls 
(P < 0.001). Radiation exposure history was 
not available for all study control subjects (13 
controls were not available for information on 
radiation exposure). However, all these 
variables were further adjusted in later 
multivariable logistic regression analyses to 
control for any residual effects. Among the 
SGC cases, the parotid gland was the most 
common anatomic site of origin for SGC 
(27.5%). The most frequently encountered 
histologic types of SGC were adenoid cystic 
carcinoma (38.4%), followed by mucoepider-
moid carcinoma (29.0%), adenocarcinoma 
(8%), acinic cell carcinoma (7.3%) carcinoma 
expleomorphic adenoma (3.6%), and salivary 
GSTM1 and GSTT1 and Salivary Gland Carcinoma 
 
 
Int J Clin Exp Med (2009) 2, 68-75 71 
duct carcinoma (3.6%), with the remaining 
10.1% consisting of several other carcinomas.  
 
Genotyping analysis results are presented in 
Table 2. The percentages of GSTM1 and 
GSTT1 null cases were higher in the SGC 
cases compared with the control group (53.0% 
vs 50.9% and 27.7% vs 20.6%, respectively), 
the differences were statistically borderline 
significant for GSTT1 (P = 0.054) but not for 
GSTM1 polymorphism (P = 0.633). The 
calculated crude ORs for the GSTM1 null 
genotype as a risk factor for SGC showed a 
minimal, statistically insignificant risk increase 
(OR, 1.1, 95% CI, 0.8-1.5). However, the crude 
OR for the GSTT1 null genotype as a risk factor 
for SGC was 1.5 (95% CI, 1.0-2.2) and was 
statistically borderline significant. A 
multivariable logistic regression analysis was 
then performed to adjust for the residual 
effects of the variables listed in Table 1, 
including age, sex, ethnicity, family cancer 
history, smoking status, alcohol status, and 
radiation exposure. After adjustment, having 
the GSTT1 null genotype remained a 
significant risk factor for SGC (OR, 1.5 [95% CI, 
Table 1. Demographic and exposure characteristics for SGC case and control subjects  
 SGC (n = 166) Controls (n = 511) P valuea 
Variable  n % n %  
Age      <0.001 
   50  64 38.6 328 64.2  
  > 50  102 61.4 183 35.8  
      
Sex      0.089 
  Male  67 40.4 245 48.0  
  Female  99 59.6 266 52.0  
      
Ethnicity      0.793 
  Non-Hispanic whites  128 77.1 399 78.1  
  Other  38 22.9 112 21.9  
      
Family cancer historyb      0.231 
  No  79 47.6 272 54.4  
  Yes  87 52.4 228 45.6  
Tobacco use      0.206 
  Current  28 16.9 104 20.4  
  Former  50 30.1 114 22.3  
  Never  88 53.0 293 57.3  
      
Alcohol use      0.759 
  Current  61 36.7 176 34.4  
  Former  21 12.7 75 14.7  
  Never  84 50.6 260 50.9  
      
Radiation exposurec      0.014 
  No  161 97.0 495 99.4  
  Yes  5 3.0 3 0.60  
aChi-square analysis comparing case subjects to control subjects; bFamily cancer history unavailable for 11 
control subjects; cRadiation exposure data unavailable for 13 control subjects. 
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1.0-2.3), and the associated risk of SGC with 
GSTM1 was not statistically significant (ORs, 
1.0, 95% CI, 0.7-1.5). 
 
Because both the null-genotypes of the GST 
polymorphisms appeared to have a minor or 
no effect on risk of SGC, we then utilized 
information from the same biologic pathway to 
perform meaningful combined effect of the 
two polymorphisms. To analyze the two 
polymorphisms together in order to focus on 
modifying effects of the combined genotypes 
on risk of SGC, we quartered the data set into 
4 groups (GSTM1/GSTT1 positive; GSTM1 
null/GSTT1 positive; GSTM1 positive/GSTT1 
null, and GSTM1/GSTT1 null (Table 3). 
Although the distribution of the combined 
genotypes was not statistically significant 
between the SGC cases and the controls (P = 
0.176), the SGC cases had a higher 
percentage of both GSTM1/ GSTT1 combined 
null genotypes than the controls. Compared 
with the combined GSTM1/GSTT1 positive 
genotypes, the combined GSTM1/GSTT1null 
genotypes were associated with a statistically 
significant risk for SGC, with a crude OR of 1.8 
(95% CI, 1.0-3.3) and adjusted OR of 1.9 (95% 
CI, 1.0-3.5). Additionally, there was a 
borderline significant dose-response 
relationship between the number of null 
Table 2. GSTT1 and GSTM1 genotype frequencies and their associations with risk of SGC 
   
SGC 
(n = 166) 
Controls 
(n = 511) 
pa 
Crude OR  
(95% CI) 
Adjusted  
ORb (95% CI) 
Genotype  n % n %   
  GSTT1      0.054        
  Wild type  120 72.3 406 79.5    Reference  Reference  
  Null  46 27.7 105 20.6    1.5 (1.0 – 2.2)  1.5 (1.0 – 2.3)  
          
  GSTM1      0.633    
  Wild type  78 47.0 251 49.1  Reference  Reference  
  Null  88 53.0 260 50.9    1.1 (0.8 – 1.5)    1.0 (0.7 – 1.5)  
aChi-square analysis comparing genotype distributions and polymorphic allele frequencies between case 
subjects and control subjects; badjusted for age, sex, ethnicity, tobacco use, family history of cancer, alcohol 
use and radiation exposure. Family cancer history unavailable for 11 control subjects and radiation exposure 
data unavailable for 13 control subjects 
 
Table 3. Combined GSTT1 and GSTM1 genotype frequencies and their associations with risk of SGC  
Combined 
genotypes 
SGC 
(n = 166) 
N          % 
Controls 
(n = 511) 
 N            % 
pa 
Crude OR  
(95% CI) 
Adjusted ORb  
(95% CI) 
Both wild typeC(ref.) 55 33.0 189 37.0 0.176 Reference Reference 
T1 wild type/M1 null 65 39.2 217 42.5  1.0 (0.7 – 1.5) 1.0 (0.6 – 1.4) 
T1 null/M1 wild type 23 13.9 62 12.1  1.3 (0.7 – 2.2) 1.2 (0.6 – 2.1) 
 Both null 23 13.9 43 8.4  1.8 (1.0 – 3.3) 1.9 (1.0 – 3.5) 
Trend test      0.050 0.061 
aChi-square analysis comparing genotype distributions and polymorphic allele frequencies between case 
subjects and control subjects; badjusted for age, sex, ethnicity, tobacco use, family history of cancer, alcohol use 
and radiation exposure. Family cancer history unavailable for 11 control subjects and radiation exposure data 
unavailable for 13 control subjects; cRef.=reference group 
 
GSTM1 and GSTT1 and Salivary Gland Carcinoma 
 
 
Int J Clin Exp Med (2009) 2, 68-75 73 
genotypes and the risk for SGC (P = 0.050 for 
crude and P = 0.061 for adjusted risk models). 
 
Discussion 
 
In this molecular epidemiologic case-control 
study of 166 SGC patients and 511 cancer-
free subjects at M.D. Anderson Cancer Center, 
we examined the association of GSTM1and 
GSTT1 null polymorphisms with the risk of 
SGC. We found that the GSTT1 null genotype 
was associated with a significantly increased 
risk of SGC. Although we did not observe a 
significant association of the GSTM1 null 
polymorphism with the risk of SGC, the 
polymorphism did appear to interact with the 
GSTT1 null polymorphism. Indeed, we found 
that participants who possess both null 
genotypes had a nearly 2-fold increased risk, 
although such individuals were not common. 
To the best of our knowledge, this is the first 
association study of GST polymorphisms and 
SGC risk.  
 
GSTM1 and GSTT1 genes are important in 
metabolizing carcinogens, and the genetic 
polymorphisms of these genes are related to 
cancer risks secondary to their differing 
abilities to activate and deactivate 
environmental carcinogens and mutagens. The 
GST enzymes have been shown to protect 
organisms from reactive oxygen compound 
damage through their abilities to bind with 
glutathione, and variations in the efficiencies 
of these enzymes may influence cancer risks 
[5, 6, 10]. Although considerable allele 
frequency differences exist among various 
ethnicities, we found a similar proportion of 
GSTM1 and GSTT1 null genotypes in the 
control population of our study (50.9% and 
20.6%, respectively) compared with those 
reported by Rebbeck et al [17]. The fact that 
radiation exposure is a clear risk factor for 
SGC further implicates an organism’s ability to 
neutralize reactive oxygen species as a 
potential risk factor for SGC. 
 
As suggested by Ho et al, in a study 
differentiated thyroid cancer [21], we also 
found that subjects with simultaneous 
presence of GSTM1 and GSTT1 null genotypes 
had a statistically significantly elevated risk for 
SGC compared with the controls, although the 
magnitude of association was modest 
(adjusted OR, 1.9). This finding indicates a 
synergistic effect of the GSTM1 and GSTT1 
null genotypes on the risk of SGC. This result 
should be plausible given the number and 
complexity of isoenzymes in the GST system 
and their variability in expression. Different 
GST isoenzymes can have overlapping 
specificity for substrates and a certain amount 
of redundancy in function, so a deficiency in 
the activity of a single GST isoenzyme may be 
compensated for by another isoenzyme. 
Consequently, lack of function in the GST 
system may be associated with increased 
cancer risk only if multiple isoenzymes are 
disabled. Although several association studies 
have suggested that GSTM1 and GSTT1 null 
genotypes are associated with the increased 
risk of several types of cancer [21-25], this is 
the only study that has focused on GST null 
genotypes and SGC. Therefore, the results 
should be confirmed in future studies with 
large sample sizes. 
 
Like any hospital-based case-control study, 
ours also has several potential limitations. 
Because all participants were enrolled from 
MD Anderson Cancer Center, our SGC and 
control groups may not have reflected the 
genetic characteristics of similar groups in the 
general population. However, because the 
variant genotype frequencies we observed in 
our control population did not differ 
significantly from the frequencies in the 
general population, it is likely that our study 
population accurately represented the general 
population. The rarity of SGC means that the 
sample size is necessarily small, so it is 
possible that our findings were caused by 
chance. A larger sample size is needed to 
detect the differential effects of GST 
polymorphisms and thereby confirm the 
findings of the current study. Finally, it is 
possible that residual effect caused by other 
confounders exists for which we did not fully 
adjust, particularly because SGC has few 
known risk factors. 
 
In summary, the findings of this molecular 
epidemiologic study suggest that the 
simultaneous presence of the GSTM1 and 
GSTT1 null genotypes is associated with an 
increased risk for SGC. This finding further 
implicates a possible relationship between 
alteration in the detoxification ability of the 
GST enzyme family and the development of 
SGC. These findings may aid in screening 
among individuals at risk for SGC and 
ultimately refine cancer prevention efforts. 
GSTM1 and GSTT1 and Salivary Gland Carcinoma 
 
 
Int J Clin Exp Med (2009) 2, 68-75 74 
However, prospective studies with larger 
sample sizes are needed to verify these 
findings. 
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